The total return over the past 12 months is +10.01% vs. +16.94% for the S&P 500. So far it's up -1.32% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +10.01% | +31.66% | +11.24% | +20.95% | +16.05% | +2.26% |
| Total Return CAGR | +10.01% | +31.66% | +11.24% | +20.95% | +16.05% | +2.26% |
| Revenue CAGR | (17.24%) | +92.44% | +4.19% | +8.32% | +22.67% | +12.39% |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Cytokinetics, Incorporated (CYTK)
| Year | Start price | End price | CYTK Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $63.54 | $62.70 | (1.32%) | +14.51% | (15.83%) |
| 2025 | $47.04 | $63.54 | +35.08% | +17.72% | +17.36% |
| 2024 | $83.49 | $47.04 | (43.66%) | +24.89% | (68.55%) |
| 2023 | $45.82 | $83.49 | +82.21% | +26.19% | +56.02% |
| 2022 | $45.58 | $45.82 | +0.53% | (18.17%) | +18.70% |
| 2021 | $20.78 | $45.58 | +119.35% | +28.74% | +90.61% |
| 2020 | $10.61 | $20.78 | +95.85% | +18.37% | +77.48% |
| 2019 | $6.32 | $10.61 | +67.88% | +31.22% | +36.66% |
| 2018 | $8.15 | $6.32 | (22.45%) | (4.56%) | (17.89%) |
| 2017 | $12.15 | $8.15 | (32.92%) | +21.70% | (54.62%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
